LAS VEGAS, Oct. 30, 2009 (GLOBE NEWSWIRE) -- A Murphy Analytics report and profile featuring BrainStorm (OTCBB:BCLI) and detailing its achievements in stem cell research has been released. This report is of potential interest to investors of leading stem cell equities Geron (Nasdaq:GERN), Osiris Therapeutics (Nasdaq:OSIR), Aastrom Biosciences (Nasdaq:ASTM) and StemCells (Nasdaq:STEM).
To view Murphy Analytic's report, and to see what rating Murphy gave BCLI, click the link below:
http://www.murphyanalytics.com/uploads/BCLI_Initiation
From the report: "As discussed later in the report, the regulatory approval process can be lengthy and expensive, but the magnitude of the potential reward for successful biotech companies is reflected in the 34.1x price / earnings multiple of the iShares Nasdaq Biotechnology Index Fund. With regard to BCLI and its near term focus on ALS specifically, there are approximately 100,000 people diagnosed with ALS globally. Although annual ALS treatment expenditures are approximately $1.25 billion in the U.S. and $3 billion globally, the average life expectancy for a patient after diagnosis is only two to five years. As an indication of the need for a new approach, there is only one drug currently approved by the FDA to slow the progression of ALS -- other treatments can only address the symptoms of the disease. Although the near-term focus is on ALS, the BCLI approach is valid for a range of neurodegenerative treatments including Parkinson Disease (PD), spinal cord injury and Huntington's Disease.
"With only one FDA approved drug demonstrated to slow the progress of ALS and a short post diagnosis life expectancy, it is clear that a better solution is needed to address this debilitating disease. As noted Dr. Clive Stevenson in 'Stem Cells and ALS - Where are We Now?' in the Fall 2008 issue of the ALS Association's 'Research ALS Today' periodical, stem cell based approaches to treatment are likely to be part of an answer."
For a corporate profile, visit: www.SmallCapSentinel.com/bcli
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCapSentinel.com is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. In exchange for advertising and investor relations services related to BCLI over a twelve-month period, IMI is the beneficial owner of 625,000 shares of BCLI held by Emerging Markets Consulting (EMC), an investor relations consultant to BCLI which has been paid 1,250,000 total shares for twelve months of investor relations and related advertising. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.